# Sweet Yarrow (Achillea fragrantissima)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/sweet-yarrow-achillea-fragrantissima
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-05
**Evidence Score:** 1 / 10
**Category:** Middle Eastern
**Also Known As:** Achillea fragrantissima, Qaysoom, Sweet yarrow, Fragrant yarrow, Desert yarrow

## Overview

Achillea fragrantissima contains sesquiterpene lactone achillolide A (AcA), flavonoid 3,5,4'-trihydroxy-6,7,3'-trimethoxyflavone (TTF), and a thujone-dominant essential oil (α-thujone up to 29.37%) that collectively modulate amyloid precursor protein [metabolism](/ingredients/condition/weight-management), suppress microglial neuro[inflammation](/ingredients/condition/inflammation), and exert [antioxidant](/ingredients/condition/antioxidant) and antibacterial activity. In Wistar rat studies, oral extract at 300–500 mg/kg significantly increased hemoglobin (5.88–5.94 g/dL versus 4.64–4.90 g/dL in controls, p<0.05) and enhanced antioxidant markers, though no human clinical trials have been conducted.

## Health Benefits

- **Wound Healing and Antibacterial Activity**: Leaf and flower extracts inhibit bacterial growth via diffusion-based assays, with thujone and fatty acids (oleic acid ~35.30% relative; palmitic acid up to 20.99%) identified as primary antimicrobial agents, supporting traditional use in wound management across Egyptian and Arabian medicine.
- **[Neuroprotective](/ingredients/condition/cognitive) Potential**: Achillolide A (AcA) reduces H2O2-induced oxidative death in astrocytes and suppresses microglial activation in vitro, suggesting a dual neuroprotective role in oxidative and neuroinflammatory conditions relevant to Alzheimer's disease pathology.
- **Amyloid Precursor Protein Modulation**: AcA (100 µM) and TTF (8 µM) upregulate full-length AβPP (~110 kDa) in cortical tissue of APPswe/PS1ΔE9 Alzheimer's model mice without altering the Aβ42/40 ratio or tau phosphorylation, indicating stabilization of AβPP processing rather than promotion of amyloidogenesis.
- **Antioxidant Capacity Enhancement**: Methanolic extracts boost total antioxidant capacity and superoxide dismutase (SOD) activity in rat models, attributed to flavonoids including TTF and phenolic acids like α-resorcylic acid, which scavenge [reactive oxygen species](/ingredients/condition/antioxidant).
- **[Immunomodulatory](/ingredients/condition/immune-support) and Hematopoietic Support**: Oral administration of A. fragrantissima extract at 300–500 mg/kg in Wistar rats significantly elevated hemoglobin levels and white blood cell counts compared to controls and echinacea-treated groups, suggesting immune-supportive and erythropoietic activity.
- **[Anti-inflammatory](/ingredients/condition/inflammation) Activity**: Sesquiterpene lactones, particularly AcA isolated from flowers, and flavonoids including TTF contribute to anti-inflammatory effects by modulating microglial activation pathways, consistent with the broader anti-inflammatory pharmacology documented across the Achillea genus.
- **Aromatic Essential Oil Bioactivity**: Hydrodistillation yields an essential oil rich in α-thujone (20.38–29.37%), artemisia ketone (19.59%), and santolina alcohol (14.66%) with demonstrated antioxidant and antimicrobial properties, forming the basis of traditional topical and inhalation preparations.

## Mechanism of Action

Achillolide A (AcA), a sesquiterpene lactone isolated from flowers, and the flavonoid TTF upregulate full-length amyloid-β protein precursor (AβPP, ~110 kDa) expression in the cortex of transgenic Alzheimer's mice while increasing ELISA-quantified Aβ40 levels, without affecting the Aβ42/40 ratio, soluble Aβ pools, AβPP C-terminal fragments, or tau phosphorylation — indicating interference with AβPP processing at a non-amyloidogenic step rather than promotion of plaque-forming cascades. AcA additionally protects primary astrocytes from hydrogen peroxide-induced oxidative death and reduces microglial hyperactivation in vitro, likely through suppression of [reactive oxygen species](/ingredients/condition/antioxidant)-mediated cell death pathways and modulation of neuro[inflammatory](/ingredients/condition/inflammation) signaling. The essential oil fraction, particularly α-thujone and associated monoterpenoids, exerts antibacterial activity through membrane-disrupting mechanisms consistent with other thujone-containing Artemisia and Achillea species, while oleic and palmitic acids contribute to membrane permeabilization of bacterial targets. Phenolic compounds including α-resorcylic acid and flavonoids enhance total antioxidant capacity and upregulate superoxide dismutase activity, suggesting direct radical scavenging alongside enzyme-level antioxidant defense modulation.

## Clinical Summary

No human clinical trials investigating Achillea fragrantissima for any health indication have been reported in the available scientific literature, representing a significant evidentiary gap given its longstanding traditional use. Available preclinical data derive from a small number of animal and cell-based studies: a transgenic mouse Alzheimer's model study demonstrated cortical AβPP upregulation with AcA and TTF treatment but did not achieve significance for all primary Aβ endpoints, limiting interpretive confidence. A Wistar rat immunology study showed statistically significant hematopoietic improvements at 300–500 mg/kg (hemoglobin increase of approximately 1.0–1.3 g/dL over controls, p<0.05), though the extract was not standardized to specific compound concentrations, reducing reproducibility. Overall, clinical confidence is very low; all described benefits remain preliminary and hypothesis-generating, requiring dose-finding, toxicokinetic, and ultimately randomized controlled human trial data before any therapeutic claims can be substantiated.

## Nutritional Profile

Achillea fragrantissima is not consumed as a dietary staple and has no characterized macronutrient profile of nutritional significance. Its phytochemical composition is well-characterized: essential oil constituents include α-thujone (20.38–29.37%), artemisia ketone (19.59%), santolina alcohol (14.66%), camphor (1.80–2.68%), borneol (0.96%), and piperatone (12.09% in HD extracts). Fatty acid fractions from methanolic leaf extracts contain oleic acid (35.30% relative, 0.56% absolute), palmitic acid (up to 20.99% under environmental stress conditions), and minor polyunsaturated fatty acids. Flavonoid content includes TTF (3,5,4'-trihydroxy-6,7,3'-trimethoxyflavone) and dihydroxanthin, while phenolic acids include α-resorcylic acid; steroidal compound strophanthidin and sesquiterpene lactone achillolide A (AcA) are present in flowers without quantified bulk concentrations reported in the literature. Bioavailability of all active constituents is unstudied in humans; DMSO was required for AcA solubilization in experimental systems, suggesting potential oral bioavailability challenges.

## Dosage & Preparation

- **Traditional Infusion (Flowers)**: Dry or fresh flower infusions prepared by steeping in hot water; no standardized dose established — used empirically in Arabian and Egyptian folk medicine for wound washing and general ailments.
- **Methanolic Leaf Extract (Research Grade)**: Used at 300–500 mg/kg in rat studies (oral administration); no human equivalent dose derived — not available as a standardized commercial supplement.
- **Essential Oil via Hydrodistillation (HD)**: HD yields approximately 84.74% of total volatiles; hydrosteam distillation (HS) yields ~93.87%; microwave-assisted HD yields ~79.82%; supercritical fluid extraction yields ~57.23% — method affects α-thujone and artemisia ketone ratios significantly.
- **Isolated AcA (In Vitro/Animal Research)**: Used at 100 µM in cell studies (72-hour exposure) and dissolved in DMSO (25 mg/mL stock) for mouse dosing; no safe human equivalent established.
- **Isolated TTF (In Vitro/Animal Research)**: Used at 8 µM in cell-based Alzheimer's model studies; no standardized human dosage or commercial preparation available.
- **Standardization**: No commercial standardization to specific actives (AcA, TTF, or thujone percentage) exists; thujone content should be monitored given neurotoxicity concerns at high doses.

## Safety & Drug Interactions

Human safety data for Achillea fragrantissima are absent; no clinical adverse event reports, maximum tolerated dose data, or pharmacovigilance records exist for this specific species. In Wistar rats, oral extract administration at up to 500 mg/kg did not produce observable toxicity and was associated with improved immune and [antioxidant](/ingredients/condition/antioxidant) markers, but formal acute and subchronic toxicology studies following GLP guidelines have not been published. The high α-thujone content of the essential oil (up to 29.37%) warrants significant caution: thujone is a known GABA-A receptor antagonist and convulsant at high doses, with neurotoxicity well-documented in structurally related Artemisia and Salvia species, and its specific toxicological threshold in A. fragrantissima essential oil preparations has not been experimentally defined. Pregnancy and lactation contraindications should be assumed given the thujone content and the abortifacient activity associated with thujone-bearing plants; potential interactions with anticonvulsants, GABAergic medications, and anticoagulants (consistent with Achillea genus pharmacology) should be considered, though no interaction data specific to this species are available.

## Scientific Research

The evidence base for Achillea fragrantissima consists entirely of in vitro cell studies, animal model experiments, and phytochemical characterization studies; no peer-reviewed human clinical trials have been published as of available data. The most mechanistically detailed preclinical work involves AcA and TTF in APPswe/PS1ΔE9 transgenic Alzheimer's mice (6 months old, 1-month treatment duration), demonstrating cortical AβPP upregulation, though sample sizes were not explicitly reported and statistical significance for key Aβ42 endpoints did not reach conventional thresholds (p=0.16 for sAβPPα). Immunohematopoietic studies in Wistar rats (implied n=6–8 per group) showed statistically significant increases in hemoglobin (p<0.05) and [white blood cell](/ingredients/condition/immune-support) counts at 300–500 mg/kg oral extract, outperforming echinacea comparator groups, but these studies lack standardized extract characterization and GLP-level methodology reporting. GC-MS and LC-MS phytochemical studies provide robust compositional data across multiple extraction methods, yet translational relevance to human dosing remains entirely speculative without bioavailability or pharmacokinetic data in any mammalian system.

## Historical & Cultural Context

Achillea fragrantissima occupies a well-documented role in traditional Arabian medicine, where it has been used for centuries as a treatment for wounds, skin conditions, gastrointestinal complaints, and respiratory ailments, with the plant's distinctive fragrance valued in both medicinal and ritual contexts across Bedouin and Egyptian communities. In Egyptian ethnobotany, it is referred to colloquially as 'sweet yarrow' or 'qaysoom' and flower infusions — both dry and fresh — have historically been applied topically to wounds and consumed internally as antipyretic and antispasmodic remedies. The Arava Valley and Sinai region served as both natural habitat and collection ground, with traditional healers harvesting aerial parts seasonally for preparation of teas, poultices, and aromatic oils. Its genus name, Achillea, references the mythological Greek hero Achilles, who according to legend used yarrow species to staunch wounds in battle — a narrative that reinforces the cross-cultural, ethnobotanical significance of wound-healing yarrow species across Mediterranean and Middle Eastern traditions.

## Synergistic Combinations

No formal synergy studies have been conducted with Achillea fragrantissima; however, based on its identified bioactive profile, combination with other flavonoid-rich [neuroprotective](/ingredients/condition/cognitive) extracts such as quercetin or baicalin may potentiate TTF-mediated AβPP modulation through additive effects on amyloid processing pathways. The antibacterial essential oil fraction, particularly α-thujone and borneol, may exhibit enhanced efficacy against Gram-positive bacteria when combined with carrier systems that improve membrane penetration, such as liposomal or nanoemulsion formulations that address the compound's known solubility limitations. Within the broader Achillea genus context, synergistic [anti-inflammatory](/ingredients/condition/inflammation) combinations with curcumin or Boswellia serrata extract targeting overlapping NF-κB and microglial activation pathways represent mechanistically plausible but entirely untested stacking strategies.

## Frequently Asked Questions

### What is Achillea fragrantissima used for in traditional medicine?

In Egyptian and Arabian traditional medicine, Achillea fragrantissima — known as 'qaysoom' or sweet yarrow — has been used primarily for wound healing, skin infections, fever, and gastrointestinal complaints. Flower infusions (both dry and fresh) were applied topically and consumed internally, with the plant harvested from arid desert regions including the Sinai Peninsula and Arava Valley. These uses align with the plant's documented antibacterial and anti-inflammatory phytochemical profile, though modern clinical validation is lacking.

### Does Achillea fragrantissima have any scientifically proven health benefits?

Preclinical evidence supports antioxidant, antibacterial, immunomodulatory, and neuroprotective activities, but no human clinical trials have been conducted to date. In Wistar rats, oral extract (300–500 mg/kg) significantly increased hemoglobin levels (5.88–5.94 g/dL versus 4.64–4.90 g/dL in controls, p<0.05) and enhanced antioxidant markers. Isolated compounds AcA and TTF demonstrated AβPP modulation in transgenic Alzheimer's mice, but these findings require human validation before therapeutic conclusions can be drawn.

### Is Achillea fragrantissima essential oil safe to use?

Safety data for this species in humans are entirely absent, and the high α-thujone content of the essential oil (up to 29.37%) is a significant concern, as thujone is a GABA-A receptor antagonist with documented neurotoxic and convulsant potential at high doses in other plant species. Rat studies using whole extract at 500 mg/kg did not reveal overt toxicity, but this was not a safety-focused study and essential oil was not the tested form. The oil should not be used during pregnancy or lactation, and use with anticonvulsant or GABAergic medications warrants caution.

### What bioactive compounds are found in Achillea fragrantissima?

The plant contains a diverse array of bioactive constituents: the essential oil is dominated by α-thujone (20.38–29.37%), artemisia ketone (19.59%), santolina alcohol (14.66%), camphor (1.80–2.68%), and borneol (~0.96%). Methanolic extracts contain fatty acids (oleic acid ~35.30% relative, palmitic acid up to 20.99%), the flavonoid TTF (3,5,4'-trihydroxy-6,7,3'-trimethoxyflavone), phenolic acid α-resorcylic acid, and steroid strophanthidin. The sesquiterpene lactone achillolide A (AcA) is isolated specifically from flowers and represents one of the most pharmacologically characterized compounds.

### What is the recommended dosage of Achillea fragrantissima supplements?

No standardized or clinically validated human dosage exists for Achillea fragrantissima in any form. Research doses used in animal studies range from 300–500 mg/kg of crude oral extract in rats, which does not translate directly to a human equivalent dose without proper pharmacokinetic data. Isolated AcA was used at 100 µM in cell studies and approximately 25 mg/mL in DMSO for mouse experiments; no commercial standardized supplement is currently available, and self-dosing is not supported by current evidence.

### Is Sweet Yarrow safe to use during pregnancy and breastfeeding?

Sweet Yarrow contains thujone and other volatile compounds that may stimulate uterine contractions, making it potentially unsafe during pregnancy and should be avoided. Limited safety data exists for breastfeeding women, so consultation with a healthcare provider is recommended before use during these periods.

### Does Sweet Yarrow interact with blood thinners or anticoagulant medications?

Sweet Yarrow has mild anticoagulant properties due to its bioactive compounds, which may potentiate the effects of blood thinners like warfarin or aspirin. Individuals taking anticoagulant medications should consult their healthcare provider before supplementing with Sweet Yarrow to avoid increased bleeding risk.

### What is the difference between Sweet Yarrow leaf extract and essential oil for wound healing?

Sweet Yarrow leaf and flower extracts contain antimicrobial fatty acids (oleic and palmitic acids) that support traditional wound care applications through direct topical contact. Essential oils are more concentrated but pose greater risks of skin irritation and toxicity when applied directly to wounds, making standardized extracts or dried herb preparations safer and more appropriate for wound management.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*